Article

Spinal cord stimulation for refractory angina pectoris and peripheral vascular disease.

The Center for Pain Relief, Charleston, West Virginia 25301, USA.
Pain physician (Impact Factor: 10.72). 11/2006; 9(4):347-52.
Source: PubMed

ABSTRACT Spinal cord stimulation has been used in clinical practice for more than three decades. The primary use of this therapy has been in spine-related disorders. In recent years, the therapy has been used more extensively in diseases of the vascular system. Increasingly, interest has piqued in using this mode of treatment for refractory angina and ischemic pain secondary to peripheral vascular disease. In this publication, we review the current literature on these two indications and present case examples of both therapies.

0 Bookmarks
 · 
116 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: The treatment of chronic limb ischemia involves the restoration of pulsatile blood flow to the distal extremity. Some patients cannot be treated with endovascular means or with open surgery; some may have medical comorbidities that render them unfit for surgery, while others may have persistent ischemia or pain even in the face of previous attempts at reperfusion. In spinal cord stimulation (SCS), a device with electrodes is implanted in the epidural space to stimulate sensory fibers. This activates cell-signaling molecules that in turn cause the release of vasodilatory molecules, a decrease in vascular resistance, and relaxation of smooth muscle cells. SCS also suppresses sympathetic vasoconstriction and pain transmission. When patient selection is based on microcirculatory parameters, SCS therapy can significantly improve pain relief, halt the progression of ulcers, and potentially achieve limb salvage.
    Methodist DeBakey cardiovascular journal 01/2013; 9(2):99-102.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Multiple studies have shown proved efficacy of spinal cord stimulation (SCS) in peripheral vascular disease (PVD). The exact mechanism by which SCS acts in the treatment of PVD is not completely understood, and may include stimulating the release of nitric oxide, modulation of the sympathetic nervous system, or modulation of prostaglandin production. Patient selection criteria have been well defined and SCS should be reserved for patients with end-stage lower limb PVD unresponsive to medical therapy and not amenable to surgical reconstruction but in whom disease has not caused inevitable limb loss. This article reviews the outcomes, techniques, patient selection criteria, and putative mechanisms of SCS for PVD.
    Neurosurgery clinics of North America 01/2014; 25(1):25-31. · 1.73 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Critical lower limb ischaemia is a diffuse pathology that could cause claudication, severe ischaemic pain and tissue loss. The common treatment includes modification of risk factors, pharmacological therapy and endovascular or surgical revascularisation of the lower limb to restore a pulsatile flow distally. Spinal cord stimulator is seen as a valid alternative in patients unsuitable for revascularisation after endovascular or surgical revascularisation failure and as adjuvant therapy in the presence of a functioning bypass in patients with extensive tissue loss and gangrene presenting a slow and difficult wound healing. We report our experience on spinal cord stimulation (SCS) indication and implantation in patients with critical lower limb ischaemia, at a high-volume centre for the treatment of peripheral arterial disease.
    International Wound Journal 04/2014; · 1.60 Impact Factor

Full-text (2 Sources)

View
1 Download
Available from
Aug 25, 2014